Sitaxsentan
Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure. IC50 value: Target: ETA receptor
Product Specifications
CAS Number
184036-34-8
Product Name Alternative
IPI 1040; TBC-11251
UNSPSC
12352005
Hazard Statement
H315-H319-H320
Target
Endothelin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cardiovascular Disease; Endocrinology
Assay Protocol
https://www.medchemexpress.com/sitaxsentan.html
Solubility
10 mM in DMSO
Smiles
O=S(C1=C(C(CC2=CC3=C(C=C2C)OCO3)=O)SC=C1)(NC4=C(C(C)=NO4)Cl)=O
Molecular Formula
C18H15ClN2O6S2
Molecular Weight
454.90
Precautions
P264-P280-P302+P352-P305+P351+P338-P362
References & Citations
[1]Chin M, Levy RD, Yoshida EM, Byrne MF.Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.Can Respir J. 2012 Jan-Feb;19 (1) :e1-2.|[2]Sandoval J, et al. STRIDE-4 investigators.Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.Pulm Pharmacol Ther. 2012 Feb;25 (1) :33-9. Epub 2011 Nov 2.|[3]Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.Vasc Health Risk Manag. 2011;7:119-24. Epub 2011 Mar 2.|[4]Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2010 Oct;299 (4) :H1118-23. Epub 2010 Aug 6.|[5]Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr. 2011 Apr;123 (7-8) :248-52. Epub 2011 Mar 31.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
ETA
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
